Key takeaways
Zidovudine (Retrovir) and Triumeq (abacavir/dolutegravir/lamivudine) are both antiretroviral medications used to treat HIV. They belong to the same drug class, HIV ARVs, and are used to prevent the virus from making copies of itself. However, they differ in several ways. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) and is often used in combination with other HIV medications, but it's not a first-choice option due to its side effects. It is available in capsule, oral solution, and IV forms and is taken multiple times a day. Triumeq, on the other hand, is a single-tablet regimen that combines three medications: abacavir, dolutegravir, and lamivudine. It is taken once daily and is available as a tablet or a dissolvable tablet for oral suspension. Zidovudine is available as a generic, while Triumeq is availible as a brand name only and requires a genetic test before starting due to the risk of a serious allergic reaction. Common side effects of zidovudine include headache and nausea, while Triumeq can cause higher blood sugar levels and trouble sleeping. Triumeq also has more drug interactions, such as with antacids and certain seizure medications.
